Milestone Pharmaceuticals names David Sandoval general counsel

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) appointed David Sandoval as General Counsel and Chief Compliance Officer, the company announced Feb. 10. The appointment coincides with Milestone's launch of CARDAMYST, a nasal spray approved by the U.S. Food and Drug Administration on Dec. 12, 2025, for treating acute episodes of paroxysmal supraventricular tachycardia in adults.

Sandoval brings over 15 years of experience in legal and compliance roles across the life sciences sector, with focus on late-stage development, regulatory approval and product commercialization. He will serve on Milestone's executive leadership team and provide legal counsel across contracts, finance, investor relations, business development, intellectual property and human resources.

Prior to joining Milestone, Sandoval served as Senior Vice President, General Counsel, Corporate Compliance Officer and Corporate Secretary at MaxCyte, Inc., where he managed global legal, compliance and risk management activities. He also held the position of Chief Legal Officer and Chief Compliance Officer for North America at Leadiant Biosciences, Inc., where he established the company's U.S. legal and compliance departments.

Earlier in his career, Sandoval held senior legal positions at Enzon Pharmaceuticals, Inc. and Eisai Inc., focusing on sales and marketing compliance matters and FDA regulatory issues. He began his legal career at O'Melveny & Myers LLP in private practice.

Sandoval holds a J.D. from New York University School of Law, a B.A. from Cornell University, and a Certificate of Business Administration from Georgetown University.

CARDAMYST is described by the company as the first approved self-administered treatment for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. The medication is also in Phase 2 development for pediatric patients with the same condition and Phase 3 development for acute treatment of atrial fibrillation with rapid ventricular rate in adults.

You May Also Be Interested In

• Sparton, Glen Eagle ink joint venture deal for Ontario silver mine
• Apptly and Koning partner on breast CT marketplace access
• MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug